Cu2+-induced self-assembly and amyloid formation of a cyclic d,l-α-peptide: Structure and function

In a wide spectrum of neurodegenerative diseases, self-assembly of pathogenic proteins to cytotoxic intermediates is accelerated by the presence of metal ions such as Cu2+. Only low concentrations of these early transient oligomeric intermediates are present in a mixture of species during fibril formation, and hence information on the extent of structuring of these oligomers is still largely unknown. Here, we investigate dimers as the first intermediates in the Cu2+-driven aggregation of a cyclic D,L-alpha-peptide architecture. The unique structural and functional properties of this model system recapitulate the self-assembling properties of amyloidogenic proteins including beta-sheet conformation and cross-interaction with pathogenic amyloids. We show that a histidine-rich cyclic D,L-alpha-octapeptide binds Cu2+ with high affinity and selectivity to generate amyloid-like cross-beta-sheet structures. By taking advantage of backbone amide methylation to arrest the self-assembly at the dimeric stage, we obtain structural information and characterize the degree of local order for the dimer. We found that, while catalytic amounts of Cu2+ promote aggregation of the peptide to fibrillar structures, higher concentrations dose-dependently reduce fibrillization and lead to formation of spherical particles, showing self-assembly to different polymorphs. For the initial self-assembly step to the dimers, we found that Cu2+ is coordinated on average by two histidines, similar to self-assembled peptides, indicating that a similar binding interface is perpetuated during Cu2+-driven oligomerization. The dimer itself is found in heterogeneous conformations that undergo dynamic exchange, leading to the formation of different polymorphs at the initial stage of the aggregation process

The violent youth of bright and massive cluster galaxies and their maturation over 7 billion years

In this study, we investigate the formation and evolution mechanisms of the brightest cluster galaxies (BCGs) over cosmic time. At high redshift (z ∼ 0.9), we selected BCGs and most massive cluster galaxies (MMCGs) from the Cl1604 supercluster and compared them to low-redshift (z ∼ 0.1) counterparts drawn from the MCXC meta-catalogue, supplemented by Sloan Digital Sky Survey imaging and spectroscopy. We observed striking differences in the morphological, colour, spectral, and stellar mass properties of the BCGs/MMCGs in the two samples. High-redshift BCGs/MMCGs were, in many cases, star-forming, late-type galaxies, with blue broad-band colours, properties largely absent amongst the low-redshift BCGs/MMCGs. The stellar mass of BCGs was found to increase by an average factor of 2.51 ± 0.71 from z ∼ 0.9 to z ∼ 0.1. Through this and other comparisons, we conclude that a combination of major merging (mainly wet or mixed) and in situ star formation are the main mechanisms which build stellar mass in BCGs/MMCGs. The stellar mass growth of the BCGs/MMCGs also appears to grow in lockstep with both the stellar baryonic and total mass of the cluster. Additionally, BCGs/MMCGs were found to grow in size, on average, a factor of ∼3, while their average Sérsic index increased by ∼0.45 from z ∼ 0.9 to z ∼ 0.1, also supporting a scenario involving major merging, though some adiabatic expansion is required. These observational results are compared to both models and simulations to further explore the implications on processes which shape and evolve BCGs/MMCGs over the past ∼7 Gyr

Use of inhibin B in recurrent ovarian granulosa cell tumors

Early diagnosis of recurrent ovarian granulose cell tumors (OGCT) remains an urgent problem of modern oncogynecology. Inhibin B is one of the most potentially important markers of OGCT. Nevertheless, in the world there are today only single studies evaluating the clinical value of inhibin B. The paper presents serum inhibin B measurements in patients with recurrent OGCT. The findings suggest that inhibin B has a high (80-100%) diagnostic sensitivity and 100% specificity

The solution structure of monomeric CCL5 in complex with a doubly sulfated N-terminal segment of CCR5.

The inflammatory chemokine CCL5, which binds the chemokine receptor CCR5 in a two-step mechanism so as to activate signaling pathways in hematopoetic cells, plays an important role in immune surveillance, inflammation, and development as well as in several immune system pathologies. The recently published crystal structure of CCR5 bound to a high-affinity variant of CCL5 lacks the N-terminal segment of the receptor that is post-translationally sulfated and is known to be important for high-affinity binding. Here, we report the NMR solution structure of monomeric CCL5 bound to a synthetic doubly sulfated peptide corresponding to the missing first 27 residues of CCR5. Our structures show that two sulfated tyrosine residues, sY10 and sY14, as well as the unsulfated Y15 form a network of strong interactions with a groove on a surface of CCL5 that is formed from evolutionarily conserved basic and hydrophobic amino acids. We then use our NMR structures, in combination with available crystal data, to create an atomic model of full-length wild-type CCR5:CCL5. Our findings reveal the structural determinants involved in the recognition of CCL5 by the CCR5 N terminus. These findings, together with existing structural data, provide a complete structural framework with which to understand the specificity of receptor:chemokine interactions

Interfacial Mineral–Peptide Properties of a Mineral Binding Peptide from Osteonectin and Bone-like Apatite

Osteonectin is a regulator of bone mineralization. It interacts specifically with collagen and apatite through its N-terminal domain, inhibiting crystal growth. In this work, we investigated the interface formed between the mineral and an acidic peptide, ON29, derived from the protein’s apatite binding domain. The structural properties of the peptide bound to the mineral and the mineral–peptide interface are characterized using NMR and computational methods. A biomaterial complex is formed by precipitation of the mineral in the presence of the acidic peptide. The peptide gets embedded between mineral particles, which comprise a disordered hydrated coat covering apatite-like crystals. ³¹P SEDRA measurements show that the peptide does not affect the overall proximity between phosphate ions in the mineral. {¹⁵N}¹³C REDOR measurements reveal an α-turn in the center of the free peptide, which is unchanged when it is bound to the mineral. {³¹P}¹³C REDOR and ¹H–¹³C HETCOR measurements show that Glu/Asp carboxylates and Thr/Ala/Val side chains from ON29 are proximate to phosphate and hydroxyl groups in the mineral phases. Predictions of ON29’s fold on and off hydroxyapatite crystal faces using ROSETTA-surface are used to model the molecular conformation of the peptide and its apatite-binding interface. The models constructed without bias from experimental results are consistent with NMR measurements and map out extensively the residues forming an interface with apatitic crystals